A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly
Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group;
AST and ALT ≤ 2.5 times the upper limit of normal for the same age group;
Serum creatinine < 2 times the upper limit of normal for the same age group;
Cardiac ejection fraction within normal limits as determined by echocardiogram. 9.Able to comply with the study visit schedule and understand and adhere to all trial protocol requirements; 10.Able to take oral medications.
Allergic to any drugs included in the trial protocol or drugs with a chemical structure similar to the investigational drug.
Chemotherapy intolerance assessed by Ferrara 2013 criteria prior to enrollment.
Hematologic relapse (bone marrow blasts or immature cells exceed 5%).
Simultaneous diagnosis of other malignant tumors in organs (requiring treatment).
Yehui Tan
Lead sponsor
The First Hospital of Jilin University
Sponsor institution